Countdown to the Call for Startup Proposals for the First S2S China Symposium as Global Top Biopharmaceutical Venture Capitalists Gather

The first S2S (Science2Startup) China Symposium, co-hosted by the world's top venture capital firm RA Capital Management and Qiming Venture Partners, will be grandly held in Hangzhou, Zhejiang on October 15, 2026. As a top-tier biotech entrepreneurship event, the call for startup proposals (on the S2S China website) from top Chinese universities and research institutions for the first S2S China Symposium is now in the countdown (deadline: March 1, 2026).

S2S (Science2Startup) is a globally renowned life science startup incubation platform. It originated in 2018 and was jointly founded by F-Prime Capital, SV Health, and Atlas Venture. It has now developed into the core engine of global biotech innovation. S2S China is jointly initiated by RA Capital Management and Qiming Venture Partners. RA Capital Management is one of the most active asset management companies in the global life science and healthcare fields. Qiming Venture Partners has a forward-looking and leading role in medical innovation investments and has consistently ranked within the top 5 globally. The combination of the two aims to accelerate the commercialization and globalization process of China's biopharmaceutical technology through the S2S platform.

The S2S Symposium is a platform for presenting the research results of selected scientists. It is an invitation-only symposium where top scientists can showcase their startup ideas and communicate with top biotech investors.

After successfully incubating more than 14 startups and successfully hosting the S2S Japan Symposium in 2024, S2S has officially set its sights on the Chinese scientific community. The first S2S China Symposium aims to build a bridge between China's world-class scientific research achievements and global top biopharmaceutical capital. It is committed to unleashing the life science potential of China's academic community and providing a showcase for early-stage research projects that have not yet received Series A financing or even established legal entities.

For this proposal call, S2S China hopes to find breakthrough technologies in the proof-of-concept stage. Ideal candidate projects should have the following characteristics:

——New proprietary academic technologies in the therapeutic field.

——Less than 4 - 5 years away from clinical application, with key data support.

——Significant advantages over existing therapies (such as better meeting unmet clinical needs).

Different from ordinary roadshows, S2S uses a unique "mentorship system" to connect selected scientists with venture capital mentors. The two parties will cooperate one-on-one to refine startup ideas and presentation materials in terms of novelty, therapeutic potential, and commercialization paths. Selected scientists will have the opportunity to directly communicate with global top investment institutions and industry executives to explore potential investment opportunities. These top investment institutions include RA Capital, Qiming Venture Partners, F-Prime, Atlas Venture, 5AM Ventures, Lilly Asia Ventures, and Hillhouse. Selected scientists will not only have potential investment opportunities but also have the chance to establish cross-border cooperation relationships. In addition, S2S China will provide travel grants for finalists to ensure the unobstructed presentation of ideas.

This is a rare opportunity to access the global top investment network. We sincerely invite top scientists to visit the official website of S2S China immediately to submit proposals and embark on the accelerated journey from the laboratory to entrepreneurship. See you in Hangzhou on October 15, 2026!